Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat and R-CHOP in Newly Diagnosed Advanced Stage DLBCL
NCT00972478Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2010
- Primary completion
- Dec 2015
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in diffuse large B-cell lymphoma (DLBCL), sponsored by National Cancer Institute. Started Nov 2010; status: active, not recruiting.
02
Drugs
vorinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00972478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00972478.